Full story
Trump's GLP-1 Drug Price Deals
Former President Donald Trump announced agreements with Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 weight-loss drugs.
“President Trump announced deals with Novo Nordisk and Eli Lilly to lower monthly out-of-pocket costs for their GLP-1 drugs Wegovy and Zepbound to between $50 and $350, down from list prices over $1,000.”
Multiple outlets reported significant price cuts for Medicare and Medicaid patients as well as some cash-pay options.
NBC News states Trump announced deals to lower monthly out-of-pocket costs for Wegovy and Zepbound to between $50 and $350.
NBC also mentions that starting doses of yet-to-be-approved oral GLP-1 drugs will be priced at $149.
CNBC adds that beneficiaries will have access to these drugs at about $245 per month, with oral tablets starting at $149 if approved.
CNBC notes that Trump introduced a TrumpRx.gov portal and a $50 monthly copay concept.
NOTUS reports similar pricing with oral GLP-1s at $149 and injectables at $245 for covered conditions.
West Asian outlet Gulf News highlights that certain groups, including Medicare and Medicaid patients, could get oral versions for as low as $150, while injectables remain more expensive.
The Washington Post describes the move as Trump securing concessions from manufacturers to lower prices for some Medicare and Medicaid patients.
Medicare Drug Coverage Timeline
Timelines and eligibility differ across reports, but most place rollout in 2026 with phased coverage and pilots.
KFI AM 640 says Medicare coverage for certain GLP-1 obesity drugs begins mid-2026.
LiveMint reports the price cuts are effective January 2026.
CNN says TrumpRx will launch in early 2026, with Medicare expansion mid-2026 and $50 copays supported by $245 Medicare prices.
CNBC emphasizes a Part D pilot covering about 10% of eligible beneficiaries, and Medicaid programs may opt in.
NBC News adds that Medicare’s 2026 premiums and copays are already set, and that new prices for 15 drugs, including GLP-1s, are expected by November 30.
WJLA notes the administration is reinstating the Most Favored Nation policy to link U.S. prices to those abroad.
Drug Pricing Variations
Reported prices vary by drug, dose, payer, and channel.
“monthly costs for Lilly’s Zepbound will drop from $1,080 to $346, and Novo’s Wegovy from $1,350 to $250, with upcoming oral GLP-1 drugs capped at $149 per month.”
Straight Arrow News says Zepbound will drop from $1,080 to $346 and Wegovy from $1,350 to $250, with oral GLP-1s capped at $149.
Daily Caller matches those figures and underscores a cap of $149 for future oral GLP-1s.
Fox Business highlights direct-to-consumer starting prices—Wegovy lowest dose at $149 and Zepbound starting at $299—with Medicare patients paying no more than $50 monthly.
WBFF similarly cites Wegovy at $149 and Zepbound at $299 via TrumpRX.
LiveMint puts typical prices around $350, with Medicare at $245 and $50 copays.
These discrepancies likely reflect different scenarios—Medicare benchmark prices, direct-to-consumer offers, lowest-dose starter pricing, and oral versus injectable formulations.
Medicare Coverage and Cost Concerns
Coverage expansion and affordability remain debated.
Quartz notes that Medicare currently does not cover these drugs for obesity despite 12.5 million potential beneficiaries.
WJLA likewise says Medicare covers GLP-1s primarily for non-obesity uses.
NBC News and Beritaja both flag implementation doubts: experts warn many patients may still face high costs and that existing Medicare rules complicate rollout.
CNN portrays the expansion as recognizing obesity as a chronic disease and calls it cost-neutral due to price cuts.
Local outlets like KAGSTV add that it’s unclear how much of the reductions will directly benefit consumers.
KFI AM 640 says experts caution some patients may still pay a lot even with the deal.
Drug Pricing Agreements Overview
The deal is part of a broader drug-pricing initiative involving “Most Favored Nation” (MFN) concepts, parallel negotiations with other pharmaceutical companies, and factual disputes regarding coverage.
“President Donald Trump announced an agreement with drugmakers Novo Nordisk and Eli Lilly to reduce the prices of their GLP-1 weight loss drugs... part of Trump’s “most favored nation” plan... Similar pricing agreements have been made with Pfizer and AstraZeneca for Medicaid drugs.”
Beritaja states that the initiative is part of Trump’s “most favored nation” plan and mentions similar pricing agreements with Pfizer and AstraZeneca.
WJLA also refers to the reinstatement of MFN and deals with several firms.
Daily Caller highlights significant U.S. manufacturing commitments by Lilly and Novo.
NBC News and Fox Business report separate agreements with Pfizer and AstraZeneca, as well as company-led direct-to-consumer programs.
There is confusion over credit and personnel: CNN attributes the agreements to the Biden administration, while most other sources credit Trump.
CNBC reports praise from “Health and Human Services Secretary Robert F. Kennedy Jr.,” a claim flagged as incorrect by El-Balad, which notes the current HHS Secretary as of 2024 is Xavier Becerra.
Some coverage diverges or includes unrelated topics: Sherwood News combines the pricing information with unrelated business news, and Daily Mail highlights weight-regain data and lifestyle advice alongside TrumpRx pricing claims.